BridgeBio Pharma Inc (BBIO)
24.58
-0.39
(-1.56%)
USD |
NASDAQ |
Apr 19, 12:19
BridgeBio Pharma Revenue (TTM): 9.303M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.303M |
| September 30, 2023 | 9.428M |
| June 30, 2023 | 5.675M |
| March 31, 2023 | 77.78M |
| December 31, 2022 | 77.65M |
| September 30, 2022 | 88.66M |
| Date | Value |
|---|---|
| June 30, 2022 | 90.67M |
| March 31, 2022 | 70.95M |
| December 31, 2021 | 69.72M |
| September 30, 2021 | 56.95M |
| June 30, 2021 | 62.74M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
5.675M
Minimum
Jun 2023
90.67M
Maximum
Jun 2022
56.32M
Average
69.72M
Median
Dec 2021
Revenue (TTM) Benchmarks
| Pfizer Inc | 58.50B |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Ardelyx Inc | 124.46M |
| Regenxbio Inc | 90.24M |
| IDEAYA Biosciences Inc | 23.38M |